- Trial phase
- Phase 2 (completed); Phase 2b planned
- Time to market
- Unknown, likely several years out. Phase 2b design is FDA-aligned but the trial had not been initiated as of the Aug 2026 update; a registrational Phase 3 and filing would still follow, so 2028+ at the earliest if all goes well.
- Why 3/10
- No hard, dated binary catalyst for imdusiran in the next ~12 months: the Phase 2 study is complete, Phase 2b is FDA-aligned but not yet initiated (per Aug 2026 Q2 earnings), and no PDUFA or scheduled topline readout exists, so the drug itself is not a near-term share-price event (score capped at 5, set at 3 given the company's near-term value is dominated by the tender offer and LNP litigation).
Near-term share-price drivers are the $230M Dutch-auction tender offer (expires Sept 29, 2026, at $5.00–$5.75) and the LNP patent lawsuits vs. Pfizer/BioNTech; watch for Phase 2b initiation announcements and conference data updates for imdusiran specifically.
Price Chart
Executive Summary
Imdusiran (development code AB-729) is Arbutus Biopharma's (Nasdaq: ABUS) lead clinical asset, an RNA-interference drug for chronic hepatitis B designed to knock down viral surface antigen and, combined with standard antivirals plus pegylated interferon, drive "functional cure." Its Phase 2 open-label study (NCT04980482, ~43 patients) is complete with results, the FDA granted Fast Track designation in April 2026, and Arbutus said in Q2 2026 earnings (Aug 2026) that it had achieved FDA alignment on the Phase 2b trial design. However, the drug has no hard, dated binary catalyst within 12 months, Phase 2b is not yet enrolling and no topline readout or regulatory decision is scheduled, and near-term stock drivers (a $230M tender offer expiring Sept 29, 2026, and LNP patent litigation versus Pfizer/BioNTech funded by a $950M Moderna settlement) are corporate, not this molecule.
How It Works
Imdusiran is a type of gene-silencing drug (RNA interference) given by injection under the skin. It carries a short piece of RNA that finds and destroys the genetic messages the hepatitis B virus uses to make its proteins, especially the viral surface antigen that keeps the immune system from clearing the infection. The idea is to combine imdusiran with standard oral hepatitis B antivirals plus an immune-stimulating interferon shot so the patient's own immune system can then achieve a durable "functional cure", a sustained loss of detectable surface antigen after stopping therapy.
Trial Status
The Phase 2 open-label study of AB-729 (imdusiran) + nucleos(t)ide analogue + pegylated interferon alfa-2a (NCT04980482, ~43 patients, Arbutus-sponsored) is COMPLETED with results, primary completion March 2025, study completion May 2025. Arbutus reported 10 patients achieving functional cure across its HBV program (March 2026 update), FDA granted Fast Track designation for chronic hepatitis B on April 15, 2026, and Q2 2026 earnings (Aug 2026) stated FDA alignment was achieved on the Phase 2b trial design, which has not yet been initiated.
The Two-Sided Case
Upcoming Catalysts
- Phase 2b trial initiation and enrollment updates for imdusiran (no fixed date announced)
- Conference/data presentations on Phase 2 functional-cure results
- Q3 2026 earnings update (likely Oct/Nov 2026), pipeline and Phase 2b timing
- Corporate (non-drug) events that will move ABUS: $230M Dutch-auction tender offer expires Sept 29, 2026, and LNP patent litigation vs. Pfizer/BioNTech progresses
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arbutus Biopharma Corp 8-K ABUS ·Originating report